On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with ...

Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.

In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $34.67, a high estimate of $81.00, and a low estimate of $4.00. Observing a ...

Return on Equity (ROE): Prothena Corp's ROE falls below industry averages, indicating challenges in efficiently using equity ...

Shares of Prothena Corporation plc (PRTA) soared on Wednesday after Danish drugmaker Novo Nordisk (NVO) said that it expects ...

The latest update is out from Prothena ( (PRTA) ).

Citizens JMP analyst Jason Butler reiterated a Buy rating on Prothena today and set a price target of $29.00. The company’s shares closed yesterday at $6.94. Elevate Your Invest ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...